Tucatinib

Drug Profile

Tucatinib

Alternative Names: ARRY-380; Irbinitinib; ONT-380

Latest Information Update: 13 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; Cascadian Therapeutics; Dana-Farber Cancer Institute
  • Class 2 ring heterocyclic compounds; Antineoplastics; Diamines; Furans; Pyridines; Quinazolinones; Small molecules; Triazoles
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain metastases; Breast cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Colorectal cancer
  • Phase I Solid tumours

Most Recent Events

  • 11 Jul 2017 Phase-II clinical trials in Breast cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Australia (PO, Tablet)
  • 11 Jul 2017 The European Medicines Agency confirms single phase II HER2CLIMB trial, if positive, could support Marketing Authorization Application and marketing approval
  • 22 Jun 2017 Phase-II clinical trials in Breast cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in France (PO, Tablet) (EudraCT2015-002801-12)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top